Newsroom

November 2016

• Press release Nov 21, 2016

  Novartis commends publication of major report which recommends broad use of dual bronchodilators to treat COPD

  2017 GOLD report recommends the first-line use of dual bronchodilators, such as Ultibro® Breezhaler®, in the treatment of the majority of symptomatic COPD patients  Bronchodilation regarded…
• Press release Nov 18, 2016

  Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator

  No clinically meaningful differences between biosimilar etanercept and the originator product in safety and efficacy over 52 weeks[1]  Innovative study design demonstrates switching between…
• Press release Nov 16, 2016

  Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study

  STRIVE, the first six-month placebo-controlled study of AMG 334 (erenumab) in migraine, met the primary endpoint, showing a statistically significant reduction in monthly migraine days versus…
• Press release Nov 16, 2016

  Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer

  First results from global registrational trial of CAR T therapy, CTL019, in pediatric relapsed/refractory acute lymphoblastic leukemia  Sub-group analyses from pivotal MONALEESA-2 trial of…
• Press release Nov 15, 2016

  New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths

  Entresto reduced the risk of first and subsequent events of heart failure hospitalizations and cardiovascular deaths following heart failure hospitalization by 20%-24% compared to enalapril[1]…
• Press release Nov 14, 2016

  Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis

  Priority Review based on data from the largest clinical trials conducted to date in each indication[1],[2] Designation will shorten FDA expected review time to within six months[3]; EMA also…
• Press release Nov 14, 2016

  Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain

  Cosentyx® data show sustained improvements in the signs and symptoms of psoriatic arthritis (PsA) in approximately 80% of patients over 3 years[1]*  New data show that with Cosentyx the high…
• Press release Nov 14, 2016

  Novartis improves ranking in 2016 Access to Medicine Index

  Novartis ranks third in 2016 ranking  Company tops the industry in access-to-medicine management and capacity building  Novartis integrated access strategy addressing all income…
• In The News Nov 10, 2016

  The price of drugs should reflect the value they deliver

  In Forbes commentary, Novartis CEO says industry should focus on outcomes for patients and healthcare systems.
• Featured News Nov 10, 2016

  When innovation draws a new future for patient treatments

  A recent summit explored how technological advances could impact patient care.

• Featured News Nov 04, 2016

  Novartis, Medikidz® and the COPD Foundation: a partnership of superhero proportions

  We teamed up with Medikidz and the COPD Foundation to develop a creative way to explain COPD to children.

• Press release Nov 01, 2016

  Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer

  Priority Review based on Phase III MONALEESA-2 trial, which showed LEE011 plus letrozole, as initial treatment for advanced breast cancer, significantly extended progression-free survival compared…